Summary

Treatment with rivaroxaban provided a simple, safe, and effective alternative to standard anticoagulation therapy for patients with deep vein thrombosis, according to findings from the phase III Oral Direct Factor Xa Inhibitor Rivaroxaban In Patients With Acute Symptomatic Deep-Vein Thrombosis Without Symptomatic Pulmonary Embolism [Einstein-DVT; NCT 00440193].